Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) (ATM-Cog)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01738191
Recruitment Status : Completed
First Posted : November 30, 2012
Last Update Posted : March 16, 2016
Michael J. Fox Foundation for Parkinson's Research
Information provided by (Responsible Party):
Vanessa Hinson, Medical University of South Carolina

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : August 2014
  Actual Study Completion Date : August 2014

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 March 10, 2017 April 20, 2017
2 October 13, 2017 November 9, 2017
3 March 26, 2018